Thaçi, D., Kimball, A., Foley, P., Poulin, Y., Levi, E., Chen, R., & Feldman, S. (2016). Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol.

Thaçi, D., A. Kimball, P. Foley, Y. Poulin, E. Levi, R. Chen, and S.R Feldman. "Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Improves Patient‐reported Outcomes in the Treatment of Moderate to Severe Psoriasis: Results of Two Phase III Randomized, Controlled Trials." J Eur Acad Dermatol Venereol 2016.

Thaçi, D., et al. "Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Improves Patient‐reported Outcomes in the Treatment of Moderate to Severe Psoriasis: Results of Two Phase III Randomized, Controlled Trials." J Eur Acad Dermatol Venereol 2016.